OR WAIT null SECS
The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.
More technologies and treatments are emerging for COVID-19—along with new variants.
Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.
August 21, 2020
CDMO Avid Bioservices will provide development and drug substance manufacturing for Oragenics’ novel COVID-19 vaccine candidate, Terra CoV-2.
August 20, 2020
UK government has set up a new organization to replace Public Health England.
EC finalizes agreement to purchase millions of doses of AstraZeneca's COVID-19 vaccine.
Novavax has signed an agreement with the UK government for 60 million doses of a COVID-19 vaccine and a Phase III clinical trial.
The collaboration will increase the supply of the potential treatment to at least three and a half times the current capacity.
A new FDA guidance provides answers to questions about when the agency will seek to visit a site during the COVID-19 pandemic and how it will respond when a needed inspection cannot be conducted safely.
August 19, 2020
Plastic primary packaging could help prevent supply chain shortages associated with high demand for COVID-19 vaccines.
August 18, 2020
FDA relies on risk assessments, border inspections, and compliance histories in place of routine audits during the COVID-19 pandemic.
August 13, 2020
SK bioscience will manufacture the vaccine antigen component for use in the final drug product at its vaccine facility in Andong L-house, South Korea.
ANA will use Quotient’s formulation and manufacturing knowledge to develop and supply the drug product for clinical trials by the third quarter of 2020.